POST-CABGDM: Empagliflozin in Perioperative CABG

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 155 participants.

Also called NCT04523064

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 155 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT04523064
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Brazil (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT04523064. Randomized; no masking; primary purpose treatment. Start 2020-09-22 (actual); primary completion 2024-01-30 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
POST-CABGDM: Empagliflozin in Perioperative CABG
Acronym
POST-CABGDM
Condition
Diabetes Mellitus, Type 2
Intervention (Drug)
Empagliflozin 25 MG
Lead sponsor
University of Sao Paulo General Hospital (class: other)

Record details

Record id
cardio:ct-nct04523064
Content hash
d8b5a84f684ef7d0b7a980f41bda1452d4a4236deb26b2437ff962821b6d1b41